---
document_datetime: 2023-09-21 19:49:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vyxeos-liposomal-epar-all-authorised-presentations_en.pdf
document_name: vyxeos-liposomal-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8665226
conversion_datetime: 2025-12-15 19:30:13.371333
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength            | Pharmaceutical Form                              | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|---------------------|--------------------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/18/1308/001 | Vyxeos liposomal  | 2.2 mg/ml / 5 mg/ml | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 44 mg;100 mg              | 1 vial      |
| EU/1/18/1308/002 | Vyxeos liposomal  | 2.2 mg/ml / 5 mg/ml | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 44 mg;100 mg              | 2 vials     |
| EU/1/18/1308/003 | Vyxeos liposomal  | 2.2 mg/ml / 5 mg/ml | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 44 mg;100 mg              | 5 vials     |